Investigators from Italy and Tunisia have reported a significantly increased prevalence of HHV-6 U94/REP antibodies among their cohort of multiple sclerosis patients. The HHV-6 U94/REP protein is associated with latency. The authors speculate that in MS there is an impairment of cellular immune response that may lead to the reactivation of HHV-6 latent infection. HHV-6 U94/REP antibodies were discovered in 51.5% of 60 patients with MS compared to 28.6% of 63 healthy controls. Mean titer values were also significantly elevated in MS patients compared to controls (1:242 vs. 1:110; p=.0005). READ MORE